AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11991463 — intervention group
Group type: COMPARATOR
Intervention: Nonbonded amalgam restorations
Number of subjects: 137
Study 11991463 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded amalgam restorations in nonretentive cavities
Number of subjects: 137
Study 10214567 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCON-L anti-adhesion barrier gel
Number of subjects: 50
Study 10214567 — intervention group
Group type: COMPARATOR
Intervention: T1-weighted axial MR images
Number of subjects: 50
Study 7783536 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg prednisone added to the current daily dose, tapering off to baseline over 18 weeks
Number of subjects: 156
Study 7783536 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 156
Study 2215615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg twice a day) and colestipol (10 g three times a day)
Number of subjects: 120
Study 2215615 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin (1 g four times a day) and colestipol (10 g three times a day)
Number of subjects: 120
Study 2215615 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (placebo or colestipol if LDL cholesterol was elevated)
Number of subjects: 120
Study 2215615 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 120
Study 2215615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin and colestipol
Number of subjects: 120
Study 2215615 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin and colestipol
Number of subjects: 120
Study 633688 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Advocacy Group
Number of subjects: 412
Study 633688 — intervention group
Group type: EXPERIMENTAL
Intervention: Halo Group
Number of subjects: 412
Study 633688 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo Group
Number of subjects: 412
Study 633688 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 412
Study 11952190 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate
Number of subjects: 136
Study 11952190 — intervention group
Group type: COMPARATOR
Intervention: Expectancy
Number of subjects: 136
Study 30427963 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic bone graft (Osteon, Dentium)
Number of subjects: 13
Study 30427963 — intervention group
Group type: COMPARATOR
Intervention: Deproteinized bovine bone (Bio-Oss)
Number of subjects: 13
Study 26695932 — intervention group
Group type: EXPERIMENTAL
Intervention: Once per week (OPW) delivery of family-based childhood obesity programme
Number of subjects: 0
Study 26695932 — intervention group
Group type: COMPARATOR
Intervention: Twice per week (TPW) delivery of family-based childhood obesity programme
Number of subjects: 0
Study 26695932 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance
Number of subjects: 0
Study 24429536 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplements twice daily
Number of subjects: 450
Study 24429536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 24429536 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplements
Number of subjects: 450
Study 22664560 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass (DJB)
Number of subjects: 18
Study 22664560 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (control group)
Number of subjects: 18
Study 20664386 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-microgram ethinyl estradiol/100-microgram levonorgestrel
Number of subjects: 226
Study 20664386 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-microgram ethinyl estradiol/150-microgram levonorgestrel
Number of subjects: 226
Study 20664386 — intervention group
Group type: COMPARATOR
Intervention: Inconsistent OCP use or nonuse
Number of subjects: 226
Study 18584469 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) system for daily reports of withdrawal, craving, and negative mood for 7 days after quitting smoking
Number of subjects: 378
Study 18584469 — intervention group
Group type: COMPARATOR
Intervention: Pencil and paper questionnaires (Minnesota Nicotine Withdrawal Scale, Questionnaire on Smoking Urges, Center for Epidemiological Studies‐Depression) completed a week after the target quit date
Number of subjects: 378
Study 15920934 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum (Freedent White)
Number of subjects: 65
Study 15920934 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthan gum-based artificial saliva (Xialine)
Number of subjects: 65
Study 11998936 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J-pouch anastomosis
Number of subjects: 42
Study 11998936 — intervention group
Group type: COMPARATOR
Intervention: Straight anastomosis
Number of subjects: 42
Study 10422532 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex wrist and forearm posture
Number of subjects: 0
Study 10422532 — intervention group
Group type: COMPARATOR
Intervention: Electrogoniometer measurements
Number of subjects: 0
Study 8657050 — intervention group
Group type: EXPERIMENTAL
Intervention: Low maintenance doses of clozapine with concomitant neuroleptic therapy
Number of subjects: 27
Study 8657050 — intervention group
Group type: COMPARATOR
Intervention: Classical neuroleptics
Number of subjects: 27
Study 2185008 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine hydrogen fumarate
Number of subjects: 12
Study 2185008 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline sulfate
Number of subjects: 12
Study 2185008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 525647 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin sulfate (500 mg, two tablets)
Number of subjects: 12
Study 525647 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone (100 mg tablet)
Number of subjects: 12
Study 30585832 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid prophylaxis (80 mg daily for 14 days)
Number of subjects: 34
Study 30585832 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid treatment (80 mg daily for 7 days between challenges)
Number of subjects: 34
Study 30585832 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 34
Study 30585832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo exposure of platelets to acetylsalicylic acid
Number of subjects: 34
Study 30075739 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Counselling Application (DCA) used by intervention providers after a two-day training program.
Number of subjects: 2625
Study 30075739 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) where providers counsel clients as before without DCA.
Number of subjects: 2625
Study 30075739 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Counselling Application (DCA) used by intervention providers.
Number of subjects: 2625
Study 27626517 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine
Number of subjects: 13900
Study 27626517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13900
Study 25218523 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 60
Study 25218523 — intervention group
Group type: COMPARATOR
Intervention: 4% lidocaine with 1:100,000 epinephrine
Number of subjects: 60
Study 25218523 — intervention group
Group type: COMPARATOR
Intervention: 4% prilocaine with 1:200,000 epinephrine
Number of subjects: 60
Study 23146657 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastoscopic axillary lymph node dissection (MALND)
Number of subjects: 1027
Study 23146657 — intervention group
Group type: COMPARATOR
Intervention: Conventional axillary lymph node dissection (CALND)
Number of subjects: 1027
Study 20605014 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonal melodies
Number of subjects: 0
Study 20605014 — intervention group
Group type: COMPARATOR
Intervention: Random melodies
Number of subjects: 0
Study 17426908 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (500 mg for 5 days)
Number of subjects: 223
Study 17426908 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg + methylprednisolone
Number of subjects: 223
Study 17426908 — intervention group
Group type: COMPARATOR
Intervention: IVIg + placebo
Number of subjects: 223
Study 17426908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain symptoms
Number of subjects: 223
Study 17426908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain severity
Number of subjects: 223
Study 17426908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain symptoms before randomization
Number of subjects: 223
Study 15593293 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolene Hernia System
Number of subjects: 334
Study 15593293 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh Plug Repair
Number of subjects: 334
Study 15593293 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein Method
Number of subjects: 334
Study 15593293 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 334
Study 11306340 — intervention group
Group type: EXPERIMENTAL
Intervention: Current heavy smokers
Number of subjects: 39876
Study 11306340 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmoking women passively exposed to cigarette smoke
Number of subjects: 39876
Study 11306340 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking women not exposed to passive smoke
Number of subjects: 39876
Study 9513842 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching
Number of subjects: 20
Study 9513842 — intervention group
Group type: COMPARATOR
Intervention: No assisted hatching (Control)
Number of subjects: 20
Study 9513842 — intervention group
Group type: COMPARATOR
Intervention: Traditional IVF (Control)
Number of subjects: 20
Study 8068956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated total body irradiation (1,320 cGy) and high-dose etoposide (60 mg/kg) followed by allogeneic bone marrow transplantation (BMT)
Number of subjects: 94
Study 3180635 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily regimen (2 mg phenobarbital tablet)
Number of subjects: 179
Study 3180635 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily regimen (2 mg phenobarbital tablet)
Number of subjects: 179
Study 3180635 — intervention group
Group type: COMPARATOR
Intervention: Thrice-daily regimen (2 mg phenobarbital tablet)
Number of subjects: 179
Study 31085338 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cut-off value for abnormal FIT result (10 or more μg hemoglobin/g feces)
Number of subjects: 17017
Study 31085338 — intervention group
Group type: COMPARATOR
Intervention: Standard cut-off value for abnormal FIT result (20 or more μg hemoglobin/g feces)
Number of subjects: 17017
Study 31013502 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0
Study 31013502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines (irisin, osteocalcin, adiponectin)
Number of subjects: 0
Study 28330649 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 3778
Study 28330649 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 3778
Study 26491284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation with 18 µg of tiotropium once daily
Number of subjects: 84
Study 26491284 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary rehabilitation alone (control group)
Number of subjects: 84
Study 23030660 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A (onabotulinumtoxinA)
Number of subjects: 22
Study 23030660 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐B (rimabotulinumtoxinB)
Number of subjects: 22
Study 23030660 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BTX‐A and BTX‐B
Number of subjects: 22
Study 22045675 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum miR-122 in APAP-ALI patients
Number of subjects: 0
Study 22045675 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum miR-192 in APAP-ALI patients
Number of subjects: 0
Study 22045675 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum miR-218 in APAP-ALI patients
Number of subjects: 0
Study 22045675 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum miR-122 in CKD patients
Number of subjects: 0
Study 22045675 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum miR-192 in CKD patients
Number of subjects: 0
Study 22045675 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of miR-122 with peak ALT levels in APAP-ALI cohort
Number of subjects: 0
Study 22045675 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 1 serum miR-122 levels in APAP-ALI patients satisfying King's College Criteria (KCC)
Number of subjects: 0
Study 19345766 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program (n=23)
Number of subjects: 48
Study 19345766 — intervention group
Group type: COMPARATOR
Intervention: Physical therapist treatment
Number of subjects: 48
Study 17227639 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 350
Study 17227639 — intervention group
Group type: COMPARATOR
Intervention: Service screening programmes
Number of subjects: 350
Study 17227639 — intervention group
Group type: COMPARATOR
Intervention: Early detection
Number of subjects: 350
Study 17227639 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast screening
Number of subjects: 350
Study 17227639 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound screening for liver cancer
Number of subjects: 350
Study 15320684 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable isometric maximum force output
Number of subjects: 10
Study 15320684 — intervention group
Group type: COMPARATOR
Intervention: Stable conditions
Number of subjects: 10
Study 15320684 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric contractions
Number of subjects: 10
Study 10997595 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin (third-generation quinolone)
Number of subjects: 0
Study 10997595 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinolones (first to third generations)
Number of subjects: 0
Study 9459089 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG
Number of subjects: 13
Study 9459089 — intervention group
Group type: COMPARATOR
Intervention: recombinant FSH
Number of subjects: 13
Study 8172088 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 2.5 mg (100,000 IU) cholecalciferol (vitamin D3)
Number of subjects: 189
Study 8172088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 2963793 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 mg three times a day rising to 7.5 mg three times a day)
Number of subjects: 11
Study 2963793 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (5 mg three times a day rising to 20 mg three times a day)
Number of subjects: 11
Study 30653372 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy activity pacing intervention
Number of subjects: 100
Study 30653372 — intervention group
Group type: COMPARATOR
Intervention: Typical occupational therapy program (control)
Number of subjects: 100
Study 30335409 — intervention group
Group type: EXPERIMENTAL
Intervention: Radon messages including smoking information (Study 1)
Number of subjects: 1045
Study 30335409 — intervention group
Group type: EXPERIMENTAL
Intervention: Radon messages with smoking information (Study 2)
Number of subjects: 1045
Study 30335409 — intervention group
Group type: EXPERIMENTAL
Intervention: Radon message describing smoking as a lung cancer risk (Study 2)
Number of subjects: 1045
Study 30335409 — intervention group
Group type: EXPERIMENTAL
Intervention: Radon message describing smoking's synergistic effect with radon (Study 2)
Number of subjects: 1045
Study 30335409 — intervention group
Group type: COMPARATOR
Intervention: Radon messages excluding smoking information (Study 2)
Number of subjects: 1045
Study 27475625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 10 mg
Number of subjects: 136
Study 27475625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 136
Study 27475625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg
Number of subjects: 136
Study 27475625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 25288512 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cannabis (22 mg THC)
Number of subjects: 54
Study 25288512 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cannabis (5.5 mg THC)
Number of subjects: 54
Study 25288512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 23897243 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic hypothermia of 33°C for 48 hours
Number of subjects: 65
Study 23897243 — intervention group
Group type: COMPARATOR
Intervention: Normothermia of 37°C
Number of subjects: 65
Study 20220045 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (oral casopitant [150 mg day 1, 50 mg days 2 and 3] and warfarin [days 1-10])
Number of subjects: 97
Study 20220045 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (oral casopitant 60 mg and warfarin [days 1-14])
Number of subjects: 97
Study 20220045 — intervention group
Group type: COMPARATOR
Intervention: Both regimens (A and B)
Number of subjects: 97
Study 18069011 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) at energy density of 0.55 mJ/mm(2) (1000 impulses)
Number of subjects: 46
Study 18069011 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment with a dummy electrode
Number of subjects: 46
Study 17211965 — intervention group
Group type: EXPERIMENTAL
Intervention: FertilityBlend (FB)
Number of subjects: 93
Study 17211965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 11883992 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 30
Study 11883992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9539614 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (200/0.5) solution
Number of subjects: 750
Study 9539614 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 750
Study 7840167 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (500 mg)
Number of subjects: 10
Study 7840167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2192406 — intervention group
Group type: COMPARATOR
Intervention: buprenorphine 4 micrograms/kg injected i.v. every 4 h (Group I)
Number of subjects: 75
Study 2192406 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.15 ml/kg injected epidurally every 2 h (Group II)
Number of subjects: 75
Study 2192406 — intervention group
Group type: COMPARATOR
Intervention: buprenorphine 4 micrograms/kg in 10 ml saline via catheter (Group III)
Number of subjects: 75
Study 2192406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regime of bupivacaine and buprenorphine (Group IV)
Number of subjects: 75
Study 96459 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine enanthate (PE) injections, dosage: 50-150 mg, duration: 2-9 days depending on sex
Number of subjects: 0
Study 96459 — intervention group
Group type: COMPARATOR
Intervention: Biperiden treatment
Number of subjects: 0
Study 7065831 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 61
Study 7065831 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadyl acetate
Number of subjects: 61
Study 7065831 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-week withdrawal
Number of subjects: 61
Study 7065831 — intervention group
Group type: COMPARATOR
Intervention: Standard three-week treatment
Number of subjects: 61
Study 31433782 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrtus communis herbal ointment
Number of subjects: 134
Study 31433782 — intervention group
Group type: COMPARATOR
Intervention: Anti-hemorrhoid ointment
Number of subjects: 134
Study 30237155 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate compression therapy (multilayer bandaging or compression hosiery, pressure 35 mm Hg)
Number of subjects: 592
Study 30237155 — intervention group
Group type: COMPARATOR
Intervention: No compression therapy
Number of subjects: 592
Study 30237155 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without RVO
Number of subjects: 592
Study 30237155 — intervention group
Group type: COMPARATOR
Intervention: Patients with RVO
Number of subjects: 592
Study 27391519 — intervention group
Group type: EXPERIMENTAL
Intervention: Transseptal suturing after septoplasty (Group A)
Number of subjects: 39
Study 27391519 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing with Merocel tampons after septoplasty (Group B)
Number of subjects: 39
Study 27391519 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Transseptal suturing and Nasal packing)
Number of subjects: 39
Study 22467404 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy
Number of subjects: 60
Study 22467404 — intervention group
Group type: COMPARATOR
Intervention: Axillary dissection
Number of subjects: 60
Study 22822237 — intervention group
Group type: COMPARATOR
Intervention: Flexibility/Balance/Function exercise (FBF)
Number of subjects: 121
Study 22822237 — intervention group
Group type: COMPARATOR
Intervention: Supervised Aerobic Exercise (AE)
Number of subjects: 121
Study 22822237 — intervention group
Group type: COMPARATOR
Intervention: Control (home-based exercise)
Number of subjects: 121
Study 19917869 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (anthracycline/taxane-based)
Number of subjects: 1058
Study 17391169 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 17391169 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol tartrate
Number of subjects: 0
Study 15756294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate fortified fish sauce
Number of subjects: 10
Study 15756294 — intervention group
Group type: COMPARATOR
Intervention: Ferrous lactate fortified fish sauce
Number of subjects: 10
Study 15756294 — intervention group
Group type: COMPARATOR
Intervention: Ferric ammonium citrate fortified fish sauce
Number of subjects: 10
Study 15756294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate fortified fish sauce with citric acid
Number of subjects: 10
Study 15756294 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate fortified fish sauce without citric acid
Number of subjects: 10